- Conditions
- Cancer Prevention, Weight Loss, Smoldering Waldenstrom Macroglobulinemia(WM), MGUS, Fasting, Multiple Myeloma
- Interventions
- Prolonged Fasting Intervention, EDUCATION CONTROL
- Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 344
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HPV
- Interventions
- Brief Provider Training - Bundled Approach, Brief Provider Training - Benefits Approach, Parent Interactive Text Message - Bundled Approach, Parent Interactive Text Message - Benefits Approach
- Behavioral
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 8,043 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Neuroendocrine Carcinoma, Neuroendocrine Tumors
- Interventions
- Seneca Valley Virus-001 (SVV-001), Nivolumab, Ipilimumab
- Biological · Drug
- Lead sponsor
- Peter Hosein, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Solid Tumors
- Interventions
- INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more
- Conditions
- Multiple Myeloma, Breast Cancer
- Interventions
- Prototype intraoperative handheld gamma camera (pIHGC), Lymphoscintigraphy with intraoperative gamma probes (GP), radioactive Tc99M
- Device · Radiation
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Gynecologic Cancer
- Interventions
- Exercise and diet education and instruction
- Behavioral
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Multiple Myeloma
- Interventions
- TAA-specific CTLs, TAA-specific CTLs- fixed dose
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 3
- States / cities
- Houston, Texas
- Conditions
- Prostatic Neoplasm
- Interventions
- Restore Rehabilitation Program, Control
- Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 403 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Neoplasms
- Interventions
- Regorafenib (Stivarga, BAY73-4506)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Aurora, Colorado • St Louis, Missouri + 2 more
- Conditions
- Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity, Cancer
- Interventions
- Stopping Heart Failure Medication(s)
- Other
- Lead sponsor
- Dinesh Thavendiranathan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 335 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- Exercise Program, Website, Exercise DVD, Survey, Self-Report Assessments
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 1,150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 3
- States / cities
- Fort Worth, Texas • Houston, Texas
- Conditions
- Lymphedema, Lymphedema of Upper Arm, Lymphedema, Breast Cancer
- Interventions
- Crossover Device (PCD or Dayspring - alternate to first group)
- Device
- Lead sponsor
- Koya Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 2
- States / cities
- Los Altos, California • Morgan Hill, California
- Conditions
- Cancer
- Interventions
- I-131-CLR1404
- Drug
- Lead sponsor
- Cellectar Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 3
- States / cities
- Duarte, California • Washington D.C., District of Columbia • Madison, Wisconsin
- Conditions
- Solid Tumors
- Interventions
- INCB053914, I-DAC (Intermediate dose cytarabine), Azacitidine, Ruxolitinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 19
- States / cities
- Tucson, Arizona • Sacramento, California • Santa Monica, California + 15 more
- Conditions
- Uncontrolled Hypertension, BMI, Stress, Medication Adherence
- Interventions
- Prime Time Sister Circle
- Behavioral
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Other
- Eligibility
- 40 Years to 75 Years · Female only
- Enrollment
- 359 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Belantamab Mafodotin, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Biological · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2034
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma
- Interventions
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Diagnostic Test · Drug · Other
- Lead sponsor
- Taproot Health
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Idaho Falls, Idaho • Laredo, Texas
- Conditions
- Breast Carcinoma
- Interventions
- Best Practice, Discussion, Interview - Stakeholder, Interview - Key Informant, Interview - Ancillary studies, Patient Navigation - C Components, Patient Navigation - B components, Patient Navigation - A components, Survey Administration, Survey Administration - Ancillary studies
- Other · Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Interventions
- ASTX727
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer
- Interventions
- 225Ac-PSMA-R2, 68Ga-PSMA-R2, 68Ga-PSMA-11
- Drug · Radiation
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma
- Interventions
- Cancer Screening, Discussion, Educational Activity, Educational Intervention, Focus Group, Health Care Delivery, Health Promotion, Health Promotion and Education, Health Risk Assessment, Implementation, Informational Intervention, Internet-Based Intervention, Interview, Outreach, Patient Navigation, Survey Administration
- Other · Behavioral · Procedure
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 2,067 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Advanced Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression
- Interventions
- 225Ac-PSMA-Trillium (BAY3563254)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 4
- States / cities
- Duarte, California • Minneapolis, Minnesota • Omaha, Nebraska + 1 more
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Interventions
- ASTX727
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Endocrine Tumors
- Interventions
- lanreotide (Autogel formulation), Placebo
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Iowa City, Iowa • Baltimore, Maryland + 5 more